

CLINICAL POLICIES, PROCEDURES & GUIDELINES

Approved by Quality & Patient Care Committee 21.4.22

OOCYTE COLLECTION - EMERGENCY TRIGGER INJECTION

This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual woman circumstances may mean that practice diverges from this LOP.

1. AIM

- To safely administer choriogonadotropin alfa (OVIDREL®) OR Triptorelin (DECAPEPTYL®) injection as a trigger prior to oocyte collection in an urgent situation, when a woman has no trigger injection or is unable to give herself the trigger injection that was ordered.

2. PATIENT

- Woman having oocyte collection for assisted reproductive therapy (ART) at the Royal Hospital for Women.

3. STAFF

- After Hours Nurse Manager (AHNM)
- Certificate in Reproductive Endocrinology and Infertility (CREI) Fellow
- Fertility Consultant
- Registered Nurse (RN)

4. EQUIPMENT

- nil

5. CLINICAL PRACTICE

The following will be the responsibility of AHNM:

- Receive call from woman and advise to present to admissions
- Collect medical record from Day Surgery Unit/Macquarie
- Inform ward of pending arrival
- Transfer woman to Macquarie ward
- Inform CREI Fellow/Fertility Consultant and obtain telephone order for medication and dosage with a second RN
- Document telephone order on National Inpatient Medication Chart (NIMC) as outlined in example below:
 - Choriogonadotropin alfa (OVIDREL®) subcutaneous (subcut) 250microgram (mcg)
ONCE (or order as number of clicks if ordered by the prescriber)
OR
 - Triptorelin (DECAPEPTYL®) subcut 400mcg ONCE

Telephone orders (to be signed within 24 hours of order)

Date time	Medicine (print generic name)	Route	Dose	Frequency	Check initials		Prescriber name	Pres. sign	Date	Record of administration			
					N1	N2				Time / given by	Time / given by	Time / given by	Time / given by
30/11/21	choriogonadotropin alfa	subcut	250 microg	ONCE	LB	MF	A Smith			/	/	/	/
	(Ovidrel)									/	/	/	/
										/	/	/	/

- Collect trigger injection from the emergency fridge at Prince of Wales Hospital (POWH)
- Observe woman administering trigger injection
- Inform the woman if her fasting time or time of theatre has changed as instructed by the CREI Fellow/Fertility Consultant

6. DOCUMENTATION

- Medical Record
- National Inpatient Medication Chart (NIMC)

7. EDUCATIONAL NOTES

- Access to emergency trigger must only be supplied to a woman who has experienced misadventure of the injection in urgent situations. e.g. incorrect storage or misfired injections.
- The medication is used to trigger ovulation in a woman undergoing in-vitro fertilization (IVF) cycles
- The oocytes need to be collected 36 hours after the administration of the trigger injection.
- Timing is critical to avoid the woman ovulating and no oocytes being available for collection
- Trigger injection is given subcutaneously to the skin in the abdomen 5cm from the umbilicus
- Choriogonadotropin alfa (OVIDREL®) comes in a pre-filled 250mcg pen with injection needles
- If the woman requires “clicks” of choriogonadotropin alfa (OVIDREL®), these are counted manually when dialling the dose.
- Triptorelin 100microg/1mL (DECAPEPTYL®) syringes are pre-loaded. Up to four syringes may be administered.
- Choriogonadotropin alfa (OVIDREL®) and Triptorelin (DECAPEPTYL®) are supplied under the Pharmaceutical Benefits Scheme and are accessed through an external pharmacy thus should not be used for any other reason apart from the indication in the LOP.
- Choriogonadotropin alfa (OVIDREL®) / Triptorelin (DECAPEPTYL®) injections are kept in the after-hours fridge at POWH
- Common side effects:
 - injection site soreness/redness
 - headache
 - tiredness
 - nausea/vomiting, abdominal pain
 - rash
- Uncommon side effects:
 - diarrhoea
 - depression
 - irritability
 - restlessness
 - breast pain
 - severe Ovarian Hyperstimulation Syndrome
 - mild allergic reaction
 - visual impairment
 - decreased urination
 - warning signs of blood clots (such as pain, warmth, redness, numbness or tingling in arm or leg) warning signs of stroke or heart attack

8. RELATED POLICIES / PROCEDURES LOCAL OPERATING PROCEDURES

- Standard First Treatment
- Women with Oncology/Medical Condition Requiring IVF / Oocyte Freezing

- Women with Breast Cancer Requiring IVF / Oocyte Freezing

9. RISK RATING

Medium

10. NATIONAL STANDARD

- Medication Safety
- Comprehensive Care
- Communicating for Safety

11. REFERENCES

1. Ovidrel® (choriogonadotropin alfa) Product Information - Last revised May 2021, accessed via eMIMS (via CIAP) November 2021
2. Decapeptyl®(Triptorelin) Product Information - Last revised November2021, accessed via eMIMS (via CIAP) November 2021.

Reviewed and Endorsed Therapeutic & Drug Utilisation Committee 21.4.22

FOR REVIEW: APRIL 2025